Jefferies Global Healthcare Conference
Logotype for Intellia Therapeutics Inc

Intellia Therapeutics (NTLA) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Intellia Therapeutics Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

HAE regulatory and clinical update

  • Lonvo-z is under priority FDA review, with a March 10, 2027 PDUFA date; FDA has said so far that an advisory committee is not needed, and review has proceeded without unusual requests.

  • The CMC review is progressing well through the FDA pilot program; prior FDA engagement helped establish standards for products like this.

  • HAE data show attacks falling to zero for most patients; all patients across Phase I–III were off long-term prophylaxis, while one outlier with ongoing attacks had essentially normal high-molecular-weight kininogen levels and may have another condition.

  • On-demand therapy use fell sharply from pretreatment levels; kallikrein knockdown follow-up extends beyond 4 years, with continued monitoring planned.

HAE launch and market access

  • Survey research found nearly 70% of patients willing to discuss lonvo-z with physicians in the first 6 months post-approval; about two-thirds of physicians expected to prescribe within the first year.

  • Initial adopters may include both patients seeking better control and well-controlled patients looking to avoid chronic therapy; Phase III outcomes were similar across patient groups.

  • Payer coverage is the launch rate-limiting step: medical exceptions are expected in the first 3 months, initial contracts and treated patients in months 3–6, and a goal of covering most HAE lives by month 9.

  • The U.S. launch is the near-term focus; ex-U.S. options include out-licensing or distribution arrangements, to be considered after establishing the U.S. launch. Management interprets cell and gene therapies as excluded from MFN considerations.

  • Management expects a high-margin, one-time product, citing synthetic manufacturing and established infrastructure; pricing and COGS details were not specified.

TTR program

  • Following the clinical hold lift, multinational sites are being reactivated; investigator enthusiasm is unchanged, patients remained in the study, and HLA status information has helped inform benefit-risk discussions.

  • HLA-positive status runs at 10%–12% across the study, varying with ethnicity and geography.

  • MAGNITUDE-2 enrollment is complete, with enrollment described as roughly 10%–15% above the target of about 60; a 9-month interim is under consideration but is not currently planned.

  • In Phase I polyneuropathy follow-up through 2 years, some patients stabilized or improved, including several who had progressed on Onpattro; Phase III is placebo-controlled, so direct comparisons with other therapies are not planned.

  • Cardiomyopathy Phase III enrollment is progressing ahead of schedule; management is evaluating potential study adjustments using external trial results and emphasizing earlier-stage patients with lower NT-proBNP.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Intellia Therapeutics